Superworth

IGC Pharma EPS IGC

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
−$0.08
Latest quarter, Q2 FY26
−$0.03
Fiscal year 2025
−$0.09

IGC Pharma's earnings per share was −$0.08 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.03.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$0.09n/a
FY2025−$0.07n/a
FY2024n/an/a
FY2021−$0.22n/a
FY2020−$0.18n/a
FY2019−$0.12n/a
FY2018−$0.07n/a
FY2017−$0.08n/a
FY2016−$0.17n/a
FY2015−$0.33n/a
FY2014−$0.37n/a
FY2013−$0.30n/a
FY2012−$2.48n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.03n/a−$0.08
Q1 FY26−$0.02n/a−$0.07
Q4 FY25−$0.01n/a−$0.07
Q3 FY25−$0.02n/a−$0.08
Q1 FY25−$0.02n/a−$0.08
Q4 FY25−$0.02n/a−$0.09
Q3 FY25−$0.02n/a−$0.11
Q2 FY25−$0.02n/a−$0.18
Q1 FY25−$0.03n/a−$0.21
Q4 FY24−$0.04n/an/a
Q3 FY24−$0.09n/an/a
Q2 FY24−$0.05n/an/a

Against its peers

Companies in Drug Manufacturers - General nearest IGC Pharma's size, closest first, today.

CompanyEPS, 12 monthsGrowth
IGCIGC Pharma−$0.08
ATNMActinium Pharmaceuticals$0.36
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
NATRNatures Sunshine Products$1.01+36% a year
Peer median$0.38

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on IGC Pharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.